<DOC>
	<DOCNO>NCT02834936</DOCNO>
	<brief_summary>This study design evaluate efficacy safety Pyrotinib patient advance pre-treated Non-small cell lung cancer With HER2 Mutation . To observe objective response rate ( ORR ) pyrotinib NSCLC With HER2 Mutation . To observe Progression free survival ( PFS ) . To assess overall survival ( OS ) . A secondary aim obtain safety information . To explore relationship biomarkers toxicity/efficacy Pyrotinib .</brief_summary>
	<brief_title>A Clinica Study Pyrotinib Patients Advanced Non-Small Cell Lung Cancer With HER2 Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . ECOG performance status 0 1 . 2 . Life expectancy 3 month . 3 . At least one measurable lesion exists . ( RECIST 1.1 ) . 4 . Histologically cytologic confirm Nonsmall cell lung cancer , Phase IIIB IV accord IASLC 2009 . 5 . Failed prior therapy . ( RECIST 1.1 ) . 6 . Confirmed HER2 mutation Central Laboratory。 7 . More one prior Platinum base chemotherapy advance and/or metastatic , recurrent NSCLC neoadjuvant adjuvant chemotherapy . 8 . Required laboratory value include follow parameter : ANC : ≥ 1.5 x 10^9/L ; Platelet count : ≥ 90 x 10^9/L ; Hemoglobin : ≥ 90 g/L ; Total bilirubin : ≤ 1.5 x upper limit normal ( ULN ) ; ALT AST : ≤2 x ULN ALT AST : ≤5x ULN patient liver metastasis ; BUN Cr : ≤1.5 x ULN； creatine clearance rate : ≥ 50 mL/min ; LVEF : ≥ 50 % ; QTcF : &lt; 470 m female &lt; 450 m male . 9 . Signed informed consent 1 . Previous therapy HER2 inhibitor . 2 . History severe hypersensitivity reaction excipients trial drug . 3 . Have clinically significant cavity effusion , pleural effusion、 pericardial effusion ascites require clinical intervention 4 . Active brain metastasis 5 . Other malignancy within past ( include primary brain tumor Leptomeningeal tumor ) , basal cell skin cancer carcinoma situ cervix 6 . Persistence clinically relevant therapy relate toxicity previous therapy ( great Common Terminology Criteria Adverse Event ( CTCAE ) 4.0 grade 1 ) 7 . Treatment surgery , chemotherapy , radiotherapy target therapy within past 4 week start therapy 8 . Uncontrolled hypertensin , diabetes . 9. unstable angina , history myocardial infarction past 6 month , congestive heart failure＞NYHA II , serious cardiac arrhythmia 10 . Active infection 11 . Variety factor affect oral medication ( unable swallow , chronic diarrhea , bowel obstruction gastrointestinal disorder abnormality 12 . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . 13 . Subjects heart disease , include : ( 1 ) angina ; ( 2 ) require medication clinically significant arrhythmia ; ( 3 ) myocardial infarction ; ( 4 ) heart failure ; ( 5 ) Any heart disease judge investigator unsuitable participate trial . 14 . Female patient pregnancy , lactation woman childbearing potential test positive baseline pregnancy test . 15 . Known history neurological psychiatric disease , include epilepsy dementia . 16 . Treatment another clinical trial within past 4 week start therapy 17 . Any condition researcher believe patient fit take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>